<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210113050028N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-01</date_registration>
      <primary_sponsor>Ardabil University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of vaginal misoprostol  and Evening primrose Capsule on the state of delivery</public_title>
      <acronym>m_epc</acronym>
      <scientific_title>Comparison of the effect of vaginal misoprostol alone and in combination with Evening primrose Capsule on the state of delivery in pregnant women candidate for pregnancy termination</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63088</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided randomly. By preparing 30 packets, 15 packets of group A (1000 mg vaginal capsule of evening primrose with 25 μg of Pfizer vaginal mesopzostol) and 15 packets of group B containing vaginal suppositories and vaginal mesoprostol tablets. Every pregnant woman will give one of the envelopes to the researcher by lot to perform delivery induction for the pregnant woman. The researcher will record all the information by attending the mothers' bedside, Blinding description: The patient receives the drug (misoprostol group and evening primrose group) in sealed packets that are encoded. The coding is done by one of the project partners and the participant, clinical caregiver, outcome assessor, data analyzer will not know the type of drug used.</study_design>
      <phase>3</phase>
      <hc_freetext>Normal Vaginal Delivery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Receiving 1000 mg vaginal capsule of evening primrose with the use of 25 μg vaginal mesopzostol by Pfizer. Intervention 2: Control group: Vaginal view medication and vaginal mesoprostol tablets.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data and results will be published as article

When:
After completing the research

To whom:
researchers

Conditions:
To help spread science

Where to obtain:
Dr. Nooshin Mobaraki_asl

How to obtain:
reference article

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Noushin Mobaraki-asl</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Varzesh squere, alavi hospital</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5613974156</zip>
        <telephone>+98 45 3323 5861</telephone>
        <email>n.mobaraki@arums.ac.ir</email>
        <affiliation>Ardabil University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Noushin Mobaraki-asl</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Varzesh squere, alavi hospital</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5613974156</zip>
        <telephone>+98 45 3323 5861</telephone>
        <email>n.mobaraki@arums.ac.ir</email>
        <affiliation>Ardabil University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Single pregnancy
live fetus
Fetal weight less than 4 kg
Amniotic fluid index   more than 5 cm
normal fetus NST
Bishop score less than 7
Absence of labor pains in the mother</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Rupture of membranes
Possibility of fetal abnormalities
need for urgent delivery
Hypersensitivity to prostaglandins and evening primrose
History of seizures
history of schizophrenia with phenothiazin Prescription
Bleeding disorders or taking anticoagulants
Fallen in FHR
Malpresentation
Fetal disorders such as hydrocephalia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Receiving 1000 mg vaginal capsule of evening primrose with the use of 25 μg vaginal mesopzostol by Pfizer</i_keyword>
      <i_keyword>Control group: Vaginal view medication and vaginal mesoprostol tablets</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Amount of pain. Timepoint: Pain measurement scale based on counting between two contractions. Method of measurement: Pain scale: The amount of pain between zero no pain and 10 most severe pain possible.</prim_outcome>
      <prim_outcome>Vaginal bleeding. Timepoint: During labor. Method of measurement: The amount of vaginal bleeding.</prim_outcome>
      <prim_outcome>Infant Weight. Timepoint: After birth. Method of measurement: Weighing the baby.</prim_outcome>
      <prim_outcome>Infant APGAR. Timepoint: 0-5-10 minutes after birth. Method of measurement: According to the standard Apgar score of infants.</prim_outcome>
      <prim_outcome>Latent &amp; active phase duration. Timepoint: From the onset of labor symptoms to the end of the active phase. Method of measurement: Latent &amp; active phase duration.</prim_outcome>
      <prim_outcome>Cervical dilatation. Timepoint: 0-10 cm. Method of measurement: Induction of cervical dilatation before and after.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of latent phase of labor. Timepoint: from the beginning of contractions to dilatation 3-6 cm. Method of measurement: Vaginal examination.</sec_outcome>
      <sec_outcome>Active phase of labor. Timepoint: From dilatation of 3-6 cm to the birth of a baby. Method of measurement: Vaginal examination.</sec_outcome>
      <sec_outcome>Method of delivery. Timepoint: Decide on the method of termination of labor. Method of measurement: Termination method of pregnancy.</sec_outcome>
      <sec_outcome>The volume of postpartum hemorrhage. Timepoint: Until the end of the labor phase. Method of measurement: Number of bloody pads.</sec_outcome>
      <sec_outcome>Pain intensity. Timepoint: every 30 minutes to 2 hours. Method of measurement: Visual Analogue Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dr. Shahrzad Gorbani(researcher)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-07</approval_date>
        <contact_name>Ethics Committee in Biomedical Research, Ardabil University of Medical Sciences</contact_name>
        <contact_address>End of Daneshgah St., Administrative Complex of Ardabil University of Medical Sciences Ardabil Ardabil Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
